Atorvastatin and Pulmonary Pressure

The comparison of atorvastatin effects with placebo on pulmonary pressure in COPD patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013051213299N1

Enrollment

Registered

2013-06-27

Start date

2013-08-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: COPD. Condition 2: Pulmonary hypertension. Chronic lower respiratory diseases Pulmonary heart disease, unspecified

Interventions

Intervention 1: Intervention group: Cap Atorvastatin, 40 mg/day, for 3 months. Intervention 2: Control group: Atorvastatin like placebo cap , 1cap/day for 3 months.

Treatment - Drugs

Intervention group: Cap Atorvastatin, 40 mg/day, for 3 months

Control group: Atorvastatin like placebo cap , 1cap/day for 3 months

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Resting pulmonary blood pressure>25mmHg; functional class II, III; ability of take part in 6 min walk test. Exclusion criteria: Cardiac diseases, Systolic blood pressure>180mmHg, Diastolic blood pressure>100mmHg, Heart rate>120/min; heart failure (LVEF<50%); no compliance, history of allergy to atorvastatin, COPD exacerbation; stroke in recent 3 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pulmonary Artery Blood Pressure. Timepoint: before and 3 months after intervention. Method of measurement: Echocardiographic study.;Right ventricle ejection fraction. Timepoint: Before intervention and 3 months later. Method of measurement: TAPSE in Echocardiographic study.;Systolic Blood Pressure. Timepoint: Before and after 6 minute walk test, before and 3 months after intervention. Method of measurement: mmHg, Mercury barometer.;Diastolic Blood Pressure. Timepoint: before and after of 6 minute walk test, before and 3 months after intervention. Method of measurement: mmHg, Mercury barometer.;Heart Rate. Timepoint: before and after 6 minute walk test, before and 3 months after intervention. Method of measurement: Rate/ Minute.;Total distance in 6MWT. Timepoint: before and 3 months after intervention. Method of measurement: Meter.	—

Measure

Time frame

Pulmonary Artery Blood Pressure. Timepoint: before and 3 months after intervention. Method of measurement: Echocardiographic study.;Right ventricle ejection fraction. Timepoint: Before intervention and 3 months later. Method of measurement: TAPSE in Echocardiographic study.;Systolic Blood Pressure. Timepoint: Before and after 6 minute walk test, before and 3 months after intervention. Method of measurement: mmHg, Mercury barometer.;Diastolic Blood Pressure. Timepoint: before and after of 6 minute walk test, before and 3 months after intervention. Method of measurement: mmHg, Mercury barometer.;Heart Rate. Timepoint: before and after 6 minute walk test, before and 3 months after intervention. Method of measurement: Rate/ Minute.;Total distance in 6MWT. Timepoint: before and 3 months after intervention. Method of measurement: Meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Cheraghi

Arak University of Medical Sciences.

dralicheraghi@arakmu.ac.ir+98 86 1417 3517

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026